The Moral Necessity to Increase Access to HCV+ Transplants With Early Treatment for HCV-naive Patients

Transplantation. 2022 Feb 1;106(2):236-238. doi: 10.1097/TP.0000000000003898.

Authors

Benjamin I Richter¹, Brendan Parent², Bonnie E Lonze³

Affiliations

¹ Department of Internal Medicine, New York University Grossman School of Medicine, New York, NY.
² Division of Medical Ethics, Department of Population Health, New York University Grossman School of Medicine, New York, NY.
³ Transplant Institute, New York University Langone Health, New York, NY.

PMID: 34342960
DOI: 10.1097/TP.0000000000003898

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use
Genotype
Hepacivirus
Hepatitis C* / diagnosis
Hepatitis C* / drug therapy
Humans
Morals
Sofosbuvir
Transplants*

Substances

Antiviral Agents
Sofosbuvir